Vincerx Financial Statements From 2010 to 2025

VINC Stock  USD 0.72  0.11  13.25%   
Vincerx Pharma financial statements provide useful quarterly and yearly information to potential Vincerx Pharma investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Vincerx Pharma financial statements helps investors assess Vincerx Pharma's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Vincerx Pharma's valuation are summarized below:
Market Capitalization
10.5 M
Earnings Share
(1.14)
We have found one hundred twenty available fundamental trend indicators for Vincerx Pharma, which can be analyzed and compared to other ratios and to its competition. Investors should ensure to double-check all of Vincerx Pharma's current performance against the performance from 2010 to 2025 to make sure the company is sustainable down the road. As of March 19, 2025, Market Cap is expected to decline to about 549 M. In addition to that, Enterprise Value is expected to decline to about 537.8 M
Check Vincerx Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Vincerx Pharma's main balance sheet or income statement drivers, such as Depreciation And Amortization of 56.8 K, Interest Expense of 8.7 M or Selling General Administrative of 12.9 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 42.32. Vincerx financial statements analysis is a perfect complement when working with Vincerx Pharma Valuation or Volatility modules.
  
Check out the analysis of Vincerx Pharma Correlation against competitors.
For information on how to trade Vincerx Stock refer to our How to Trade Vincerx Stock guide.

Vincerx Pharma Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets19.9 M20.9 M18.7 M
Slightly volatile
Other Current Liabilities1.7 M1.8 M3.5 M
Pretty Stable
Total Current Liabilities7.5 M6.4 MM
Slightly volatile
Accounts PayableM2.9 M893.6 K
Slightly volatile
Non Current Assets Total2.8 MM1.2 M
Slightly volatile
Common Stock Total Equity800900981
Slightly volatile
Common Stock Shares Outstanding17.3 M24.5 M10.5 M
Slightly volatile
Liabilities And Stockholders Equity19.9 M20.9 M18.7 M
Slightly volatile
Non Current Liabilities Total2.3 M1.6 M929.4 K
Slightly volatile
Other Stockholder Equity117.8 M195.9 M53.1 M
Slightly volatile
Total Liabilities9.1 MM3.7 M
Slightly volatile
Capital Stock1.8 K2.3 K1.3 K
Slightly volatile
Common Stock1.8 K2.3 K1.3 K
Slightly volatile
Other Assets0.860.9159.7 K
Pretty Stable
Cash And Short Term Investments10.9 M11.5 M54.9 M
Slightly volatile
Capital Surpluse33.6 M37.8 M41.3 M
Slightly volatile
Other Current Assets1.6 M2.2 M1.4 M
Slightly volatile
Short and Long Term Debt Total2.7 M2.3 M3.8 M
Slightly volatile
Short Term Debt1.2 MM1.5 M
Pretty Stable
Property Plant EquipmentM2.9 M3.9 M
Slightly volatile
Other Liabilities40 K45 K49.1 K
Slightly volatile
Net Receivables966.4 K939.6 K1.3 M
Slightly volatile
Non Current Liabilities Other40 K45 K49.1 K
Slightly volatile

Vincerx Pharma Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization56.8 K59.8 K124.6 K
Slightly volatile
Selling General Administrative12.9 M15.7 M5.5 M
Slightly volatile
Selling And Marketing Expenses16.4 M15.7 M5.4 M
Slightly volatile
Other Operating Expenses41.2 M49 M17.4 M
Slightly volatile
Total Operating Expenses41.2 M49 M17.4 M
Slightly volatile
Research Development35 M32.3 M16.6 M
Slightly volatile
Cost Of Revenue650.9 K1.1 M362.5 K
Slightly volatile
Non RecurringM4.5 M4.9 M
Slightly volatile

Vincerx Pharma Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation3.9 M4.1 M3.1 M
Slightly volatile
Other Cashflows From Financing Activities97.5 K102.6 K46.6 M
Slightly volatile
Depreciation561.9 K1.1 M451.8 K
Slightly volatile
Total Cash From Financing Activities97.5 K102.6 K49.6 M
Slightly volatile
Change To Liabilities844.8 K1.2 M409 K
Slightly volatile
Sale Purchase Of Stock800900981
Slightly volatile
Cash And Cash Equivalents Changes49.4 M55.6 M60.6 M
Slightly volatile
Cash Flows Other Operating3.5 M3.9 M4.3 M
Slightly volatile
Change To Account Receivables290.4 K377.2 K224.7 K
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Capex To Depreciation12.3713.9215.1747
Slightly volatile
Payables Turnover0.40.423.2103
Slightly volatile
Cash Per Share0.660.691.0419
Slightly volatile
Days Payables Outstanding937896522
Slightly volatile
Income Quality0.580.910.6846
Slightly volatile
Current Ratio2.873.0213.3695
Slightly volatile
Debt To Equity0.210.20.0753
Slightly volatile
Capex Per Share0.250.280.301
Slightly volatile
Graham Net Net0.30.310.8488
Slightly volatile
Interest Debt Per Share0.10.110.0463
Slightly volatile
Debt To Assets0.130.120.0544
Slightly volatile
Days Of Payables Outstanding937896522
Slightly volatile
Ebt Per Ebit0.690.850.9379
Slightly volatile
Total Debt To Capitalization0.170.160.0662
Slightly volatile
Debt Equity Ratio0.210.20.0753
Slightly volatile
Quick Ratio2.873.0213.378
Slightly volatile
Net Income Per E B T0.841.010.9378
Slightly volatile
Cash Ratio2.492.6211.4695
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.931.041.1359
Slightly volatile
Debt Ratio0.130.120.0544
Slightly volatile

Vincerx Pharma Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap549 M577.9 M4.2 B
Slightly volatile
Enterprise Value537.8 M566.1 M4.1 B
Slightly volatile

Vincerx Fundamental Market Drivers

Cash And Short Term Investments12.8 M

Vincerx Upcoming Events

26th of March 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
26th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Vincerx Pharma Financial Statements

Vincerx Pharma stakeholders use historical fundamental indicators, such as Vincerx Pharma's revenue or net income, to determine how well the company is positioned to perform in the future. Although Vincerx Pharma investors may analyze each financial statement separately, they are all interrelated. For example, changes in Vincerx Pharma's assets and liabilities are reflected in the revenues and expenses on Vincerx Pharma's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Vincerx Pharma. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue-591.3 K-561.7 K
Cost Of Revenue1.1 M650.9 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Vincerx Pharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Vincerx Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Vincerx Pharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Vincerx Pharma Stock:
Check out the analysis of Vincerx Pharma Correlation against competitors.
For information on how to trade Vincerx Stock refer to our How to Trade Vincerx Stock guide.
You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vincerx Pharma. If investors know Vincerx will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vincerx Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.14)
Return On Assets
(0.66)
Return On Equity
(1.42)
The market value of Vincerx Pharma is measured differently than its book value, which is the value of Vincerx that is recorded on the company's balance sheet. Investors also form their own opinion of Vincerx Pharma's value that differs from its market value or its book value, called intrinsic value, which is Vincerx Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vincerx Pharma's market value can be influenced by many factors that don't directly affect Vincerx Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Vincerx Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Vincerx Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vincerx Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.